Compare Virgin Galactic Holdings, Inc. (SPCE) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Virgin Galactic Holdings, Inc. vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Virgin Galactic Holdings, Inc. trades at $2.94 (market cap $456.30M), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 127.5× Virgin Galactic Holdings, Inc.'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.36% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Virgin Galactic Holdings, Inc. for 69 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days on average.
| SPCE | TAK | |
|---|---|---|
Market Cap | $456.30M | $58.16B |
Volume | 4,518,834 | 2,467,530 |
Sector | Industrials | Health |
52-Week High | $7.52 | $19.05 |
52-Week Low | $2.17 | $13.23 |
Typical Hold Time | 69 Days | 0 Days |
Enterprise Value | $420.29M | $86.04B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPCE trades at $2.94, down 4.23% today, reflecting a bearish technical outlook amid persistent fundamental challenges. The company continues to report significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have seen earnings beats. Cash flow remains negative, but trends show improvement, with a projected positive net cash flow of $25M in 2026. Analyst sentiment is mixed, with a Buy/Hold/Sell split of 29%/41%/29%.
The outlook remains high-risk due to ongoing cash burn and delayed commercial flights, but strong ticket demand and a path to positive cash flow by 2027 offer long-term potential. Investors face substantial volatility and dilution risks, requiring careful risk management.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
